Kathua to become India’s antibiotic powerhouse with Rs 600 crore pharma facility

A groundbreaking ceremony led by Union Minister Jitendra Singh has marked the start of a new Rs 600 crore pharmaceutical manufacturing plant in Kathua. This state-of-the-art facility will specialise in producing Amino Cephalosporanic Acid, a vital component of antibiotics. With this investment, India is set to bolster its pharmaceutical sector and lessen dependence on foreign imports.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yeDE8hu
via IFTTT

Read More

West Asia war hits medical tourism: Overseas patient flow to Indian hospitals drops up to 75%

Israel-Iran war: Indian hospitals face a sharp decline in international patients. The ongoing conflict has disrupted travel, causing revenue losses. Hospitals report a 50% to 75% fall in overseas patient flows. This situation is prompting a shift towards attracting patients from Southeast Asia, Africa, and Central Asia. Recovery depends on regional stability and travel confidence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/K07jhvu
via IFTTT

Read More

Ambuja Neotia Group to develop over Rs 700 cr integrated healthcare and hospitality project in Guwahati

Ambuja Neotia Group will build a large integrated healthcare and hospitality project in Guwahati. The Rs 700 crore investment will include a 300-bed multi-speciality hospital and a 4+ star hotel. This initiative aims to boost the region's healthcare infrastructure and economy. The project is expected to create thousands of jobs. It marks the group's second healthcare venture in Assam.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xielzBA
via IFTTT

Read More

'India has intellectual power to be a leader in biomedical innovation,' says Bayer AG

Bayer's CEO Bill Anderson believes India can become a top pharmaceutical market. He highlights the need for supportive policy frameworks, including stronger intellectual property protection. This will attract investment in cutting-edge drugs. India's young population and technological leadership offer significant opportunities. Bayer is investing in innovation centers in Bengaluru, leveraging Indian talent for global missions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kN8cZl1
via IFTTT

Read More

India warns drugmakers against direct or surrogate weight-loss drug and obesity ads

India's drug regulator has issued a stern warning to pharmaceutical companies. Direct or indirect advertising of weight-loss medicines is now prohibited. Obesity awareness campaigns that promote prescription drugs are also under scrutiny. This move comes as global and domestic companies vie for a share of India's growing obesity drug market. The regulator emphasizes that misleading promotions will face action.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qvqk8LB
via IFTTT

Read More

India medical device shortage: Polypropylene price surge threatens syringes, IV bags amid Iran war

India's medical devices industry faces a polypropylene shortage due to the Iran war, causing a sharp price increase of over Rs 55 per kg. This surge, coupled with a deepening gas supply crisis impacting syringe production, threatens small and medium enterprises and overall healthcare delivery.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jPJiAtX
via IFTTT

Read More

Govt cautions pharma cos against surrogate ads for promoting GLP-1 drugs

Weight loss drug risks: The government has warned of strict regulatory action against those found using surrogate advertising to promote GLP-1 drugs. "A detailed advisory on the use of GLP-1 drugs is expected to be released in the next few days," sources told ET.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9AnrLdw
via IFTTT

Read More